Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alimta, Gemzar, and Avastin in first-line non-squamous NSCLC
NCT00438204Phase 2Terminated
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- May 2006
- Primary completion
- Mar 2013
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, gemcitabine, pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Barbara Ann Karmanos Cancer Institute. Started May 2006; status: terminated.
02
Drugs
bevacizumabgemcitabinepemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00438204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00438204.